Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Natalizumab in the treatment of rheumatoid arthritis in subjects receiving methotrexate
Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation.
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
MYRAC Rx
Gray matter is targeted in first-attack multiple sclerosis.
Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination.
MS and NMO: Partners No More.
CD4 cell response to interval therapy with natalizumab.
Liver X receptors alpha and beta promote myelination and remyelination in the cerebellum.
Intermittent feeding attenuates clinical course of experimental autoimmune encephalomyelitis in C57BL/6 mice.
IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.
NAD⁺ in aging, metabolism, and neurodegeneration.
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
Electroacupuncture Promotes the Differentiation of Transplanted Bone Marrow Mesenchymal Stem Cells Pre-Induced with Neurotrophin-3 and Retinoic Acid into Oligodendrocyte-Like Cells in Demyelinated Spinal Cord of Rats.
CD46: The 'multitasker' of complement proteins.
Central nervous system lymphoma associated with natalizumab.
MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.
Cyclophosphamide for multiple sclerosis.
The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis.
Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle.
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study.
De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.
Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia.
Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon.
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.

Pages